All In Biotech

Drug Trial Radar · NCT00074724

Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization

Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 319 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

319

Actual

Start

May 2003

Primary completion

Dec 2008

Study completion Apr 2017

Sponsor

Lead sponsor
Medstar Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Dec 23, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To define the role of the assessment of myocardial viability with dobutamine echocardiography (DE) in the clinical evaluation and selection of the best treatment for a high-risk subset of patients with coronary artery disease.

Conditions

  • Cardiovascular Diseases
  • Coronary Disease
  • Heart Failure
  • Heart Failure, Congestive
  • Heart Diseases

Interventions

  • Coronary Artery BypassProcedure

    coronary revascularization using arterial or vein conduits

  • Modern medical managementDrug

    Therapies with evidence-based recommendations.

  • Dobutamine echocardiographyDevice

    Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.

  • Optimal medical therapyDrug

    All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival Free of Cardiac HospitalizationTime frame: 3 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.